Nova Mentis Life Science Corp. Logo

Nova Mentis Life Science Corp.

NMLSF

(1.5)
Stock Price

0,02 USD

-2385.69% ROA

73.69% ROE

-2.99x PER

Market Cap.

1.882.284,21 USD

-5.74% DER

0% Yield

0% NPM

Nova Mentis Life Science Corp. Stock Analysis

Nova Mentis Life Science Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Nova Mentis Life Science Corp. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (-34.98x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

4 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

5 ROE

The stock's ROE indicates a negative return (-696.26%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-872.41%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Nova Mentis Life Science Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Nova Mentis Life Science Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Nova Mentis Life Science Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Nova Mentis Life Science Corp. Revenue
Year Revenue Growth
2005 488
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 7.192 100%
2020 11.472 37.31%
2021 0 0%
2022 0 0%
2023 113.384 100%
2023 28.346 -300%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Nova Mentis Life Science Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 724.735 100%
2017 93.865 -672.1%
2018 22.109 -324.56%
2019 0 0%
2020 31.323 100%
2021 860.074 96.36%
2022 115.163 -646.83%
2023 724 -15806.49%
2023 71.151 98.98%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Nova Mentis Life Science Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 0
2006 100.034 100%
2007 0 0%
2008 705.253 100%
2009 1.641.865 57.05%
2010 646.746 -153.87%
2011 895.221 27.76%
2012 650.735 -37.57%
2013 186.992 -248%
2014 490.461 61.87%
2015 703.908 30.32%
2016 1.236.234 43.06%
2017 1.703.012 27.41%
2018 3.530.673 51.77%
2019 1.213.982 -190.83%
2020 1.765.086 31.22%
2021 2.069.010 14.69%
2022 1.818.319 -13.79%
2023 634.548 -186.55%
2023 857.773 26.02%
2024 112.220 -664.37%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Nova Mentis Life Science Corp. EBITDA
Year EBITDA Growth
2005 -62.240
2006 -101.722 38.81%
2007 -614.191 83.44%
2008 -744.193 17.47%
2009 -1.839.102 59.53%
2010 -692.982 -165.39%
2011 -976.934 29.07%
2012 -654.953 -49.16%
2013 -112.565 -481.84%
2014 1.082.988 110.39%
2015 -723.003 249.79%
2016 -1.847.260 60.86%
2017 -1.730.827 -6.73%
2018 -3.652.196 52.61%
2019 -1.109.631 -229.14%
2020 19.676.355 105.64%
2021 -3.080.929 738.65%
2022 -1.167.098 -163.98%
2023 -759.828 -53.6%
2023 -1.202.299 36.8%
2024 -360.680 -233.34%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Nova Mentis Life Science Corp. Gross Profit
Year Gross Profit Growth
2005 488
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 -641 100%
2016 -588 -9.01%
2017 -3.016 80.5%
2018 -8.647 65.12%
2019 1.626 631.8%
2020 1.729 5.96%
2021 -4.998 134.59%
2022 -3.792 -31.8%
2023 113.384 103.34%
2023 25.405 -346.31%
2024 -2.308 1200.74%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Nova Mentis Life Science Corp. Net Profit
Year Net Profit Growth
2005 -62.563
2006 -87.400 28.42%
2007 -516.154 83.07%
2008 -505.684 -2.07%
2009 -1.782.287 71.63%
2010 -2.536.956 29.75%
2011 -3.313.116 23.43%
2012 -6.597.809 49.78%
2013 -263.293 -2405.88%
2014 -2.060.930 87.22%
2015 -689.154 -199.05%
2016 -2.075.266 66.79%
2017 -1.865.943 -11.22%
2018 -3.573.099 47.78%
2019 -1.398.087 -155.57%
2020 -23.248.988 93.99%
2021 -2.684.619 -766.01%
2022 -2.465.886 -8.87%
2023 -736.256 -234.92%
2023 -1.224.422 39.87%
2024 -362.312 -237.95%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Nova Mentis Life Science Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 -1
2006 -1 0%
2007 -2 100%
2008 -2 -100%
2009 -4 66.67%
2010 -3 -50%
2011 -2 -100%
2012 -2 50%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Nova Mentis Life Science Corp. Free Cashflow
Year Free Cashflow Growth
2005 -178.830
2006 -360.437 50.39%
2007 -1.153.489 68.75%
2008 -672.607 -71.5%
2009 -2.487.933 72.97%
2010 -781.312 -218.43%
2011 -2.231.200 64.98%
2012 -140.220 -1491.21%
2013 -173.359 19.12%
2014 -489.542 64.59%
2015 -707.483 30.81%
2016 -767.374 7.8%
2017 -1.512.839 49.28%
2018 -1.415.763 -6.86%
2019 -878.811 -61.1%
2020 -422.109 -108.2%
2021 -1.946.198 78.31%
2022 -1.443.614 -34.81%
2023 -277.531 -420.16%
2023 -171.679 -61.66%
2024 -9.761 -1658.83%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Nova Mentis Life Science Corp. Operating Cashflow
Year Operating Cashflow Growth
2005 -71.699
2006 -74.518 3.78%
2007 -384.240 80.61%
2008 -514.985 25.39%
2009 -1.240.991 58.5%
2010 -675.770 -83.64%
2011 -1.091.268 38.07%
2012 -133.115 -719.79%
2013 -168.359 20.93%
2014 -489.282 65.59%
2015 -706.627 30.76%
2016 -767.374 7.92%
2017 -1.503.023 48.94%
2018 -1.375.138 -9.3%
2019 -878.811 -56.48%
2020 -856.530 -2.6%
2021 -1.946.198 55.99%
2022 -1.443.614 -34.81%
2023 -277.531 -420.16%
2023 -171.679 -61.66%
2024 -9.761 -1658.83%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Nova Mentis Life Science Corp. Capital Expenditure
Year Capital Expenditure Growth
2005 107.131
2006 285.919 62.53%
2007 769.249 62.83%
2008 157.622 -388.03%
2009 1.246.942 87.36%
2010 105.542 -1081.47%
2011 1.139.932 90.74%
2012 7.105 -15944.08%
2013 5.000 -42.1%
2014 260 -1823.08%
2015 856 69.63%
2016 0 0%
2017 9.816 100%
2018 40.625 75.84%
2019 0 0%
2020 -434.421 100%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Nova Mentis Life Science Corp. Equity
Year Equity Growth
2005 157.437
2006 625.791 74.84%
2007 1.595.160 60.77%
2008 1.848.509 13.71%
2009 4.106.384 54.98%
2010 2.879.136 -42.63%
2011 7.924.577 63.67%
2012 1.351.558 -486.33%
2013 1.279.800 -5.61%
2014 126.751 -909.7%
2015 199.292 36.4%
2016 653.444 69.5%
2017 3.065.722 78.69%
2018 7.241.742 57.67%
2019 6.259.865 -15.69%
2020 4.709.142 -32.93%
2021 459.102 -925.73%
2022 41.344 -1010.44%
2023 -601.043 106.88%
2023 -810.603 25.85%
2024 -1.045.560 22.47%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Nova Mentis Life Science Corp. Assets
Year Assets Growth
2005 161.344
2006 682.958 76.38%
2007 1.615.038 57.71%
2008 1.916.658 15.74%
2009 4.192.707 54.29%
2010 2.959.311 -41.68%
2011 7.949.307 62.77%
2012 1.691.378 -369.99%
2013 1.596.959 -5.91%
2014 274.492 -481.79%
2015 303.502 9.56%
2016 729.944 58.42%
2017 3.224.887 77.37%
2018 7.550.696 57.29%
2019 6.584.935 -14.67%
2020 5.092.104 -29.32%
2021 881.158 -477.89%
2022 296.785 -196.9%
2023 53.887 -450.75%
2023 31.059 -73.5%
2024 26.348 -17.88%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Nova Mentis Life Science Corp. Liabilities
Year Liabilities Growth
2005 3.907
2006 57.167 93.17%
2007 19.878 -187.59%
2008 68.149 70.83%
2009 86.323 21.05%
2010 80.175 -7.67%
2011 24.730 -224.2%
2012 339.820 92.72%
2013 317.159 -7.14%
2014 147.741 -114.67%
2015 104.210 -41.77%
2016 76.500 -36.22%
2017 159.165 51.94%
2018 308.954 48.48%
2019 325.070 4.96%
2020 382.962 15.12%
2021 422.056 9.26%
2022 255.441 -65.23%
2023 654.930 61%
2023 841.662 22.19%
2024 1.071.908 21.48%

Nova Mentis Life Science Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-2.99x
Price To Sales Ratio
0x
POCF Ratio
-28.74
PFCF Ratio
-28.79
Price to Book Ratio
-1.8
EV to Sales
0
EV Over EBITDA
-3.04
EV to Operating CashFlow
-29.52
EV to FreeCashFlow
-29.52
Earnings Yield
-0.33
FreeCashFlow Yield
-0.03
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.03
Graham NetNet
-0.01

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.1
ROE
0.74
Return On Assets
-23.86
Return On Capital Employed
0.6
Net Income per EBT
1
EBT Per Ebit
1
Ebit per Revenue
0
Effective Tax Rate
-0.06

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.69
Return on Tangible Assets
-23.86
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,01
Tangible Book Value per Share
-0.01
Shareholders Equity per Share
-0.01
Interest Debt per Share
0
Debt to Equity
-0.06
Debt to Assets
2.28
Net Debt to EBITDA
-0.08
Current Ratio
0.02
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-1045561
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
-3735.5
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Nova Mentis Life Science Corp. Dividends
Year Dividends Growth

Nova Mentis Life Science Corp. Profile

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp., through its subsidiaries, engages in developing diagnostics and psilocybin based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome in Canada. It is also involved in the research and development of anti-inflammatory effects of psilocybin for metabolic indications, such as obesity and diabetes; and development of cannabis products. Nova Mentis Life Science Corp. has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.

CEO
Ms. Rebecca Lynn Hudson C.A.,
Employee
0
Address
700-838 West Hasting Street
Vancouver, V6C 0A6

Nova Mentis Life Science Corp. Executives & BODs

Nova Mentis Life Science Corp. Executives & BODs
# Name Age
1 Ms. Rebecca Lynn Hudson C.A., CPA
Chief Financial Officer
70

Nova Mentis Life Science Corp. Competitors